US/UK/Canada

Share

Contacts

  • Pål Ryfors

    CEO


    Karlavägen 60, 114 49 Stockholm
    0709623669
    http://www.episurf.com
    • Pick a time period -
    Tags ( Active)

    Episurf Medical’s Prof. Leif Ryd to be amongst faculty at Orthopaedic Summit 2022: Evolving Techniques

    Episurf Medical (Nasdaq: EPIS B) today announces that the company's founder and board member Prof. Leif Ryd will participate in the Orthopaedic Summit 2022: Evolving Techniques (OSET), which will take place between September 21-24 in Boston, Massachusetts, USA. The Orthopaedic Summit is a gathering of Total Joint (Knee, Hip, Shoulder), Foot & Ankle, Sports Medicine, Arthroscopic, Spine and Trauma Surgeons from the global orthopaedic industry. The meeting is expected to host more than 1,000 delegates including medical professionals and industry representatives. Prof. Ryd is amongst an

    Episurf Medical to present at Redeye Life Science Day today, November 11[th], 2021

    Episurf Medical (Nasdaq: EPIS B) will attend Redeye Life Science Day which is held today, November 11th, 2021. The event is arranged by Redeye and the company will be represented by its founder Prof. Leif Ryd. The presentation will be streamed live at 15:40 CET at https://www.redeye.se/events/815899/redeye-life-science-day-2021 and will also be made available afterwards on our website www.episurf.com.

    Members of the Nomination Committee for Episurf Medical’s Annual General Meeting in 2021

    In accordance with decision by the Annual General Meeting, Episurf Medical’s Nomination Committee shall consist of four members. The members are selected by the three largest shareholders in the company that wish to participate in the committee. In addition, the Chairman of the Board is to be appointed to the Nomination Committee. In accordance with the above principles, the Nomination Committee consists of the following four members: · Dennis Stripe, Chairman of the Board of Episurf Medical AB · Leif Ryd, representing Niles Noblitt · Robert Charpentier, representing Carl

    Results from Swedish multi-centre clinical trial with follow-up of 30 Episealer® patients accepted for scientific publication

    Episurf Medical (Nasdaq: EPIS B) today announces that results from a clinical study with follow-up of the 30 first Episealer® patients from nine Swedish clinics has been accepted for publication in the scientific journal Cartilage. The publication is expected to be available online shortly. The study reports on good implant safety and significantly improved patient-reported outcome scores. In total, 30 patients are included in the study and the average follow-up time is 55 months (subjective outcome scores at 24 months, survival data at 24 – 86 months, mean of 55 months). The Episealer®

    Episurf Medical to present at Redeye Growth Day on June 2, 2020

    Episurf Medical (Nasdaq: EPIS B) will attend Redeye Growth Day on June 2 2020. The event is arranged by Redeye and the company will be represented by the Founder Leif Ryd and CEO Pål Ryfors. The presentation will be available live at 15:15 on https://www.redeye.se/newevents/585379/growth-day-1. The presentation will also be available after the conference at Redeye’s website, as well as on the company’s website. For more  information, please contact: Pål Ryfors, CEO, Episurf MedicalTel:+46 (0) 709 62 36 69Email: pal.ryfors@episurf.com   About Episurf Medical Episurf

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media